Abatacept

For the prevention of rheumatoid arthritis to become feasible, it may be necessary to intervene as soon as possible in the pre-RA course, although the specific timing remains unclear, according to a speaker at the EULAR 2023 Congress.

DESTIN, Fla. — Complicated disease pathogenesis and a lack of FDA-approved therapies makes sarcoidosis a significant clinical challenge, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

Reactivation of double-stranded DNA viruses is an important cause of morbidity and mortality after hematopoietic stem cell transplantation.

Nearly two-thirds of patients with rheumatoid arthritis meet the criteria for at least one sleep disorder, according to data published in Arthritis Care & Research.

Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.

DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.

The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.

SALT LAKE CITY — Abatacept demonstrated efficacy among patients with steroid-refractory chronic graft-versus-host-disease, according to phase 2 study results.

Physical function and MRI scores predict flares at 6 and 12 months following the end of treatment with abatacept among patients with early rheumatoid arthritis in remission, according to data published in Arthritis Research & Therapy.

The FDA approved abatacept in combination with a calcineurin inhibitor and methotrexate for prevention of acute graft versus host disease.